134 related articles for article (PubMed ID: 6546354)
1. [3H]Pirenzepine identifies putative M1 muscarinic receptors in human stellate ganglia.
Watson M; Roeske WR; Johnson PC; Yamamura HI
Brain Res; 1984 Jan; 290(1):179-82. PubMed ID: 6546354
[TBL] [Abstract][Full Text] [Related]
2. Light microscopic autoradiographic localization of [3H]pirenzepine and [3H](-)quinuclidinyl benzilate binding in human stellate ganglia.
Yamamura HI; Watson M; Wamsley JK; Johnson PC; Roeske WR
Life Sci; 1984 Aug; 35(7):753-7. PubMed ID: 6547993
[TBL] [Abstract][Full Text] [Related]
3. [3H]pirenzepine and (-)-[3H]quinuclidinyl benzilate binding to rat cerebral cortical and cardiac muscarinic cholinergic sites. II. Characterization and regulation of antagonist binding to putative muscarinic subtypes.
Watson M; Roeske WR; Yamamura HI
J Pharmacol Exp Ther; 1986 May; 237(2):419-27. PubMed ID: 3754581
[TBL] [Abstract][Full Text] [Related]
4. High-affinity [3H]pirenzepine binding to putative M1 muscarinic sites in the neuroblastoma x glioma hybrid cell line (NG 108-15).
Akiyama K; Watson M; Roeske WR; Yamamura HI
Biochem Biophys Res Commun; 1984 Feb; 119(1):289-97. PubMed ID: 6546688
[TBL] [Abstract][Full Text] [Related]
5. Differential ontogeny of putative M1 and M2 muscarinic receptor binding sites in the murine cerebral cortex and heart.
Evans RA; Watson M; Yamamura HI; Roeske WR
J Pharmacol Exp Ther; 1985 Dec; 235(3):612-8. PubMed ID: 3841156
[TBL] [Abstract][Full Text] [Related]
6. A unique regulatory profile and regional distribution of [3H]pirenzepine binding in the rat provide evidence for distinct M1 and M2 muscarinic receptor subtypes.
Watson M; Yamamura HI; Roeske WR
Life Sci; 1983 Jun; 32(26):3001-11. PubMed ID: 6688111
[TBL] [Abstract][Full Text] [Related]
7. Characterization of [3H]pirenzepine binding to muscarinic cholinergic receptors solubilized from rat brain.
Luthin GR; Wolfe BB
J Pharmacol Exp Ther; 1985 Jul; 234(1):37-44. PubMed ID: 3839265
[TBL] [Abstract][Full Text] [Related]
8. Comparison of [3H]pirenzepine and [3H]quinuclidinylbenzilate binding to muscarinic cholinergic receptors in rat brain.
Luthin GR; Wolfe BB
J Pharmacol Exp Ther; 1984 Mar; 228(3):648-55. PubMed ID: 6546770
[TBL] [Abstract][Full Text] [Related]
9. [3H]pirenzepine and (-)-[3H]quinuclidinyl benzilate binding to rat cerebral cortical and cardiac muscarinic cholinergic sites. I. Characterization and regulation of agonist binding to putative muscarinic subtypes.
Watson M; Yamamura HI; Roeske WR
J Pharmacol Exp Ther; 1986 May; 237(2):411-8. PubMed ID: 3754580
[TBL] [Abstract][Full Text] [Related]
10. Muscarinic receptor subtypes in human nasal mucosa: characterization, autoradiographic localization, and function in vitro.
Okayama M; Mullol J; Baraniuk JN; Hausfeld JN; Feldman B; Merida M; Shelhamer JH; Kaliner MA
Am J Respir Cell Mol Biol; 1993 Feb; 8(2):176-87. PubMed ID: 8427708
[TBL] [Abstract][Full Text] [Related]
11. Characterization of high affinity [3H]pirenzepine and (-)-[3H] quinuclidinyl benzilate binding to muscarinic cholinergic receptors in rabbit peripheral lung.
Bloom JW; Halonen M; Lawrence LJ; Rould E; Seaver NA; Yamamura HI
J Pharmacol Exp Ther; 1987 Jan; 240(1):51-8. PubMed ID: 3806397
[TBL] [Abstract][Full Text] [Related]
12. Effects of in vivo and in vitro treatments with N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline on putative muscarinic receptor subtypes in rat brain.
Norman AB; Creese I
Mol Pharmacol; 1986 Aug; 30(2):96-103. PubMed ID: 3755499
[TBL] [Abstract][Full Text] [Related]
13. Effects of bilateral ibotenate-induced lesions of the nucleus basalis magnocellularis upon selective cholinergic biochemical markers in the rat anterior cerebral cortex.
Watson M; Vickroy TW; Fibiger HC; Roeske WR; Yamamura HI
Brain Res; 1985 Nov; 346(2):387-91. PubMed ID: 3840399
[TBL] [Abstract][Full Text] [Related]
14. Studies on muscarinic binding sites in human brain identified with [3H]pirenzepine.
Lin SC; Olson KC; Okazaki H; Richelson E
J Neurochem; 1986 Jan; 46(1):274-9. PubMed ID: 2866235
[TBL] [Abstract][Full Text] [Related]
15. Gallamine binding to muscarinic M1 and M2 receptors, studied by inhibition of [3H]pirenzepine and [3H]quinuclidinylbenzilate binding to rat brain membranes.
Burke RE
Mol Pharmacol; 1986 Jul; 30(1):58-68. PubMed ID: 3755217
[TBL] [Abstract][Full Text] [Related]
16. The differential loss of [3H]pirenzepine vs [3H] (-) quinuclidinylbenzilate binding to soluble rat brain muscarinic receptors indicates that pirenzepine binds to an allosteric state of the muscarinic receptor.
Roeske WR; Venter JC
Biochem Biophys Res Commun; 1984 Feb; 118(3):950-7. PubMed ID: 6546685
[TBL] [Abstract][Full Text] [Related]
17. Multiple binding affinities of N-methylscopolamine to brain muscarinic acetylcholine receptors: differentiation from M1 and M2 receptor subtypes.
el-Fakahany EE; Ramkumar V; Lai WS
J Pharmacol Exp Ther; 1986 Aug; 238(2):554-63. PubMed ID: 3755473
[TBL] [Abstract][Full Text] [Related]
18. Muscarinic cholinergic receptors in the human spinal cord: differential localization of [3H]pirenzepine and [3H]quinuclidinylbenzilate binding sites.
Villiger JW; Faull RL
Brain Res; 1985 Oct; 345(1):196-9. PubMed ID: 3840715
[TBL] [Abstract][Full Text] [Related]
19. Muscarinic antagonist binding site heterogeneity as evidenced by autoradiography after direct labeling with [3H]-QNB and [3H]-pirenzepine.
Wamsley JK; Gehlert DR; Roeske WR; Yamamura HI
Life Sci; 1984 Apr; 34(14):1395-402. PubMed ID: 6546776
[TBL] [Abstract][Full Text] [Related]
20. [3H]Pirenzepine and [3H]quinuclidinyl benzilate binding to brain muscarinic cholinergic receptors. Differences in measured receptor density are not explained by differences in receptor isomerization.
Luthin GR; Wolfe BB
Mol Pharmacol; 1984 Sep; 26(2):164-9. PubMed ID: 6548291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
